Increased XPO1 levels have been observed in a variety of malignancies including CD138+ PCs from patients with active MM and are associated with poor survival outcomes, making XPO1 an attractive molecular target for novel therapies [251]. The gene discussed is SDC1; the disease is Miyoshi myopathy.